0A8M Stock Overview
Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Aytu BioPharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.31 |
| 52 Week High | US$3.50 |
| 52 Week Low | US$1.40 |
| Beta | -1.23 |
| 1 Month Change | 11.26% |
| 3 Month Change | 3.28% |
| 1 Year Change | 90.23% |
| 3 Year Change | -97.07% |
| 5 Year Change | n/a |
| Change since IPO | -97.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A8M | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 8.2% | 2.9% | 2.3% |
| 1Y | 90.2% | 7.8% | 5.5% |
Return vs Industry: 0A8M exceeded the UK Pharmaceuticals industry which returned 7.8% over the past year.
Return vs Market: 0A8M exceeded the UK Market which returned 5.5% over the past year.
Price Volatility
| 0A8M volatility | |
|---|---|
| 0A8M Average Weekly Movement | 7.6% |
| Pharmaceuticals Industry Average Movement | 8.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0A8M has not had significant price volatility in the past 3 months.
Volatility Over Time: 0A8M's weekly volatility has decreased from 14% to 8% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 150 | Josh Disbrow | aytubio.com |
Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.
Aytu BioPharma, Inc. Fundamentals Summary
| 0A8M fundamental statistics | |
|---|---|
| Market cap | US$18.65m |
| Earnings (TTM) | -US$18.00m |
| Revenue (TTM) | US$98.50m |
0.2x
P/S Ratio-1.0x
P/E RatioIs 0A8M overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A8M income statement (TTM) | |
|---|---|
| Revenue | US$98.50m |
| Cost of Revenue | US$36.20m |
| Gross Profit | US$62.29m |
| Other Expenses | US$80.29m |
| Earnings | -US$18.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | -3.23 |
| Gross Margin | 63.24% |
| Net Profit Margin | -18.27% |
| Debt/Equity Ratio | 48.7% |
How did 0A8M perform over the long term?
See historical performance and comparison